Africa

MSF Launches Ervebo Study for 20,000 DR Congo Ebola Frontline Workers

Read this story on The State of Israel

Published

Courtroom-sketch editorial illustration of an Indian peacekeeper receiving an Ebola vaccination from a health worker at a field clinic in Pinga, North Kivu, in an archival 2019 scene that does not depict the September 2026 MSF study, rendered in warm ochre and slate-blue pastel strokes.

MSF and its epidemiology center Epicentre launched the BRAVO study on September 19 at the World Health Organization-run training center in Bunia. The project aims to enroll 20,000 health-care and frontline workers in Ituri and North Kivu to test whether the licensed Ervebo vaccine offers protection against the Bundibugyo Ebola virus driving the current outbreak. MSF said the study will last 9 to 12 months, with three months of vaccination and at least six months of follow-up. Participation is voluntary, and the research supplements rather than replaces infection-prevention measures.

Sources

Primary sources:1

Related stories

  1. DR Congo Ebola Outbreak Reaches 60 Health Zones as Toll Rises to 2,786
  2. DR Congo Ebola Outbreak Kills 317 in One Week as Toll Reaches 2,642
  3. First Ervebo Doses Land in Kinshasa as DR Congo Fights Its Deadliest Ebola Outbreak

Something went wrong

We couldn't complete that action. Check your connection and try again.